C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by C4 Therapeutics, Inc. on October 15, 2024. The filing discloses significant changes in executive leadership, specifically the departure of the Chief Scientific Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of Chief Scientific Officer: Stewart Fisher, Ph.D., is retiring as Chief Scientific Officer. His departure is effective upon the start date of his successor, expected on October 28, 2024. The departure is not due to any disagreement with the Company.
- Appointment of Chief Scientific Officer: Paige Mahaney, Ph.D., has been appointed as the new Chief Scientific Officer, effective October 28, 2024. She joins from Exelixis, Inc., where she served as senior vice president and corporate head of drug discovery.
Compensation and Inducement Details
Stewart Fisher (Outgoing):
- Will serve as Senior Scientific Advisor through December 31, 2024.
- Will serve as a consultant providing transitional services from December 31, 2024, through December 31, 2025.
- Equity awards held as of December 31, 2024, will continue to vest through December 31, 2025.
- May be paid an hourly rate for project-based services if mutually agreed upon.
Paige Mahaney (Incoming):
- Base Salary: $510,000 annually.
- Sign-on Bonus: $150,000.
- Relocation Allowance: Up to $75,000.
- Performance Bonus: Up to 40% of base salary, contingent on employment for the full preceding calendar year.
- Stock Options: Option to purchase 345,600 shares at the last reported price on the commencement date. Vesting schedule: 25% on the first anniversary, with the balance vesting in equal monthly installments over the next three years.
- Restricted Stock Units (RSUs): 76,800 shares vesting in equal annual installments over four years.
Risks and Contingencies
The filing states that Dr. Fisher's departure was not caused by any disagreement regarding operations, policies, or practices. No other material risks or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the exact commencement date of Dr. Mahaney's employment (expected October 28, 2024) to confirm the start of the vesting schedules.
- Review the impact of the new equity grants (345,600 options and 76,800 RSUs) on potential dilution.
- Confirm the transition plan for scientific leadership between Dr. Fisher and Dr. Mahaney to ensure continuity in drug discovery and pipeline advancement.
- Check subsequent filings for the formal execution of the Consulting Agreement with Dr. Fisher and the Employment Agreement with Dr. Mahaney.